@Article{096504019X15555428221646,
AUTHOR = {Prasanna Rajagopalan, Abdulrahim Hakami, Mohammed Ragab, Ashraf Elbessoumy},
TITLE = {FCY-302, a Novel Small Molecule, Induces Apoptosis in Leukemia and Myeloma  Cells by Attenuating Key Antioxidant and Mitochondrial Enzymes},
JOURNAL = {Oncology Research},
VOLUME = {27},
YEAR = {2019},
NUMBER = {8},
PAGES = {957--964},
URL = {http://www.techscience.com/or/v27n8/48624},
ISSN = {1555-3906},
ABSTRACT = {Arylidene analogs are well proven for biological activities. FCY-302, a novel small molecule belonging to 
this class, was screened for its biological efficacy in leukemia and myeloma cells. FCY-302 selectively inhibited proliferation of cancer cells with GI50 values of 395.2 nM, 514.6 Nm, and 642.4 nM in HL-60, Jurkat, 
and RPMI-8226 cells, respectively. The compound also increased sub-G0 peak in the cancer cell cycle and 
favored apoptosis determined by annexin V assay. The compound decreased the antiapoptotic Bcl-2 levels and 
increased proapoptotic Bax proteins in leukemia and myeloma cell lines. FCY-302 attenuated the mitochondrial membrane-bound Na<sup>+</sup>
/K<sup>+</sup>
 ATPase, Ca<sup>2+</sup> ATPase, and Mg<sup>2+</sup> ATPase enzyme activities and significantly 
decreased activities of antioxidant enzymes like SOD, CAT, G<sub>R</sub>, and GST in all the three cancer cells tested. 
Our findings suggest that FCY-302 inhibits the proliferation of leukemia and myeloma cancer cells by altering 
key mitochondrial and antioxidant enzymes, eventually driving them to apoptosis. These results drive focus on 
FCY-302 and its analogs to be developed as potential small molecules with bioactivities against cancer.},
DOI = {10.3727/096504019X15555428221646}
}